doxepin has been researched along with Day Blindness in 2 studies
Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.
doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rickels, K | 1 |
| Feighner, JP | 1 |
| Smith, WT | 1 |
| Pigott, PV | 1 |
2 trials available for doxepin and Day Blindness
| Article | Year |
|---|---|
Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression.
Topics: Adult; Alcoholism; Alprazolam; Ambulatory Care; Amitriptyline; Anti-Anxiety Agents; Benzodiazepines; | 1985 |
A review of clinical studies with combinations of fluphenazine and nortriptyline.
Topics: Amitriptyline; Anxiety; Central Nervous System; Clinical Trials as Topic; Depression; Diazepam; Doxe | 1972 |